How Halotestin (Fluoxymesterone) Affects HDL Cholesterol

Halotestin (fluoxymesterone) combines every factor that maximises oral steroid HDL toxicity into a single compound:

1. 17-alpha-alkylation and first-pass HTGL stimulation: Halotestin's 17-AA structure allows full first-pass survival, delivering a concentrated androgenic signal to hepatocytes. This massively upregulates hepatic triglyceride lipase (HTGL), accelerating HDL catabolism.
2. Extreme androgenic potency: Halotestin has one of the highest androgenic ratings of any AAS. The hepatic androgenic signal per milligram is disproportionately high, driving intense HTGL upregulation even at the lower end of the dose range.
3. No aromatisation: Halotestin does not convert to estradiol. As with other non-aromatising 17-AA orals (stanozolol, superdrol), the absence of estrogenic activity eliminates the partial HTGL brake that estradiol normally provides.
4. Fluorine substitution extends hepatic exposure: The 9-alpha-fluorine group on fluoxymesterone increases metabolic resistance to hepatic degradation. This means halotestin remains active in hepatocytes longer per dose than most other 17-AA compounds, prolonging HTGL stimulation per dose.
5. ApoA-I suppression: Reduces production of apolipoprotein A-I, impairing de novo HDL synthesis alongside the accelerated catabolism.

The result is a compound that maximises every lipid-toxic mechanism: first-pass concentration, extreme androgenic potency, zero estrogenic offset, and extended hepatic residence.

At 10-20 mg/day (lower contest-prep doses):

• Severe HDL suppression: 50-80%+ reduction from baseline
• Single-digit HDL values (below 10 mg/dL) are commonly reported
• LDL rises sharply, creating a severely atherogenic ratio

At 30-40 mg/day (typical contest-prep doses):

• HDL suppression of 70-80%+ is expected
• Single-digit or zero-measurable HDL values have been reported
• Total cholesterol:HDL ratio can exceed 10:1 to 15:1, representing extreme cardiovascular risk
• Triglycerides also commonly rise, reflecting broad hepatic lipid metabolism impairment

Timing:

• First-pass mechanism means HTGL changes begin within hours
• Significant HDL falls within the first week
• Maximum suppression often reached by week 2-3, consistent with other potent 17-AA orals

Comparison:

• The lipid impact is comparable to or worse than superdrol, which is itself among the worst of any commonly used compound

Baseline lipid panel and liver enzymes are both mandatory:

• Halotestin is highly hepatotoxic as well as severely lipid-toxic; both must be assessed at baseline
• Do not start halotestin with pre-existing dyslipidemia or elevated liver enzymes

On cycle:

• Check lipids and liver enzymes (ALT, AST, GGT) at 2 weeks
• If HDL is below 15 mg/dL at week 2, strong consideration should be given to stopping
• If ALT or AST exceed 3-5x upper limit of normal, stopping is strongly recommended regardless of the lipid panel

Post-cycle:

• Recheck lipids and liver enzymes at 4 and 8 weeks post-cessation
• If HDL remains below 20 mg/dL at 6 weeks post-cycle, consult a physician for cardiovascular risk assessment

Duration restriction is the primary intervention:

• Typical use is 2-4 weeks, almost exclusively in pre-contest contexts
• This is not primarily a safety choice; it reflects the extreme psychoactive androgenic effects that are unsustainable long-term
• The lipid damage at 2-4 weeks is already severe; longer use is not justified from any risk-benefit perspective

Aggressive supplementation during use:

• Omega-3 EPA/DHA: 3-4 g/day
• Citrus bergamot: 1,000 mg/day
• TUDCA: 500 mg/day for liver support (halotestin is among the most hepatotoxic AAS; liver protection is as important as lipid management)
• Psyllium husk: 5-10 g/day

Post-cycle continuation:

• Continue all lipid and liver supplements for 8-12 weeks post-use
• Increase cardiovascular exercise volume during recovery

Stacking prohibition:

• Never stack halotestin with other oral 17-AA compounds. The hepatotoxicity and lipid toxicity are additive.
• Never combine with other hepatotoxic agents (alcohol, high-dose NSAIDs)